Towards precision medicine

Advances in 5-hydroxymethylcytosine cancer biomarker discovery in liquid biopsy

Chang Zeng, Emily Kunce Stroup, Zhou Zhang, Brian C.H. Chiu, Wei Zhang*

*Corresponding author for this work

Research output: Contribution to journalReview article

1 Citation (Scopus)

Abstract

Robust and clinically convenient biomarkers for cancer diagnosis, early detection, and prognosis have great potential to improve patient survival and are the key to precision medicine. The advent of next-generation sequencing technologies enables a more sensitive and comprehensive profiling of genetic and epigenetic information in tumor-derived materials. Researchers are now able to monitor the dynamics of tumorigenesis in new dimensions, such as using circulating cell-free DNA (cfDNA) and tumor DNA (ctDNA). Mutation-based assays in liquid biopsy cannot always provide consistent results across studies due partly to intra- and inter-tumoral heterogeneity as well as technical limitations. In contrast, epigenetic analysis of patient-derived cfDNA is a promising alternative, especially for early detection and disease surveillance, because epigenetic modifications are tissue-specific and reflect the dynamic process of cancer progression. Therefore, cfDNA-based epigenetic assays are emerging to be a highly sensitive, minimally invasive tool for cancer diagnosis and prognosis with great potential in future precise care of cancer patients. The major obstacle for applying epigenetic analysis of cfDNA, however, has been the lack of enabling techniques with high sensitivity and technical robustness. In this review, we summarized the advances in epigenome-wide profiling of 5-hydroxymethylcytosine (5hmC) in cfDNA, focusing on the detection approaches and potential role as biomarkers in different cancer types.

Original languageEnglish (US)
Article number12
JournalCancer Communications
Volume39
Issue number1
DOIs
StatePublished - Mar 29 2019

Fingerprint

Precision Medicine
Tumor Biomarkers
Epigenomics
Biopsy
DNA
Neoplasms
Biomarkers
Early Detection of Cancer
5-hydroxymethylcytosine
Early Diagnosis
Patient Care
Carcinogenesis
Research Personnel
Technology
Mutation
Survival

Keywords

  • 5-Hydroxymethylcytosine
  • Cancer biomarker
  • Cell-free DNA
  • Epigenetics
  • Liquid biopsy

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Zeng, Chang ; Stroup, Emily Kunce ; Zhang, Zhou ; Chiu, Brian C.H. ; Zhang, Wei. / Towards precision medicine : Advances in 5-hydroxymethylcytosine cancer biomarker discovery in liquid biopsy. In: Cancer Communications. 2019 ; Vol. 39, No. 1.
@article{a5d4a8a26cd249a28da7e2269b901435,
title = "Towards precision medicine: Advances in 5-hydroxymethylcytosine cancer biomarker discovery in liquid biopsy",
abstract = "Robust and clinically convenient biomarkers for cancer diagnosis, early detection, and prognosis have great potential to improve patient survival and are the key to precision medicine. The advent of next-generation sequencing technologies enables a more sensitive and comprehensive profiling of genetic and epigenetic information in tumor-derived materials. Researchers are now able to monitor the dynamics of tumorigenesis in new dimensions, such as using circulating cell-free DNA (cfDNA) and tumor DNA (ctDNA). Mutation-based assays in liquid biopsy cannot always provide consistent results across studies due partly to intra- and inter-tumoral heterogeneity as well as technical limitations. In contrast, epigenetic analysis of patient-derived cfDNA is a promising alternative, especially for early detection and disease surveillance, because epigenetic modifications are tissue-specific and reflect the dynamic process of cancer progression. Therefore, cfDNA-based epigenetic assays are emerging to be a highly sensitive, minimally invasive tool for cancer diagnosis and prognosis with great potential in future precise care of cancer patients. The major obstacle for applying epigenetic analysis of cfDNA, however, has been the lack of enabling techniques with high sensitivity and technical robustness. In this review, we summarized the advances in epigenome-wide profiling of 5-hydroxymethylcytosine (5hmC) in cfDNA, focusing on the detection approaches and potential role as biomarkers in different cancer types.",
keywords = "5-Hydroxymethylcytosine, Cancer biomarker, Cell-free DNA, Epigenetics, Liquid biopsy",
author = "Chang Zeng and Stroup, {Emily Kunce} and Zhou Zhang and Chiu, {Brian C.H.} and Wei Zhang",
year = "2019",
month = "3",
day = "29",
doi = "10.1186/s40880-019-0356-x",
language = "English (US)",
volume = "39",
journal = "Cancer Communications",
issn = "1000-467X",
publisher = "BioMed Central Ltd.",
number = "1",

}

Towards precision medicine : Advances in 5-hydroxymethylcytosine cancer biomarker discovery in liquid biopsy. / Zeng, Chang; Stroup, Emily Kunce; Zhang, Zhou; Chiu, Brian C.H.; Zhang, Wei.

In: Cancer Communications, Vol. 39, No. 1, 12, 29.03.2019.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Towards precision medicine

T2 - Advances in 5-hydroxymethylcytosine cancer biomarker discovery in liquid biopsy

AU - Zeng, Chang

AU - Stroup, Emily Kunce

AU - Zhang, Zhou

AU - Chiu, Brian C.H.

AU - Zhang, Wei

PY - 2019/3/29

Y1 - 2019/3/29

N2 - Robust and clinically convenient biomarkers for cancer diagnosis, early detection, and prognosis have great potential to improve patient survival and are the key to precision medicine. The advent of next-generation sequencing technologies enables a more sensitive and comprehensive profiling of genetic and epigenetic information in tumor-derived materials. Researchers are now able to monitor the dynamics of tumorigenesis in new dimensions, such as using circulating cell-free DNA (cfDNA) and tumor DNA (ctDNA). Mutation-based assays in liquid biopsy cannot always provide consistent results across studies due partly to intra- and inter-tumoral heterogeneity as well as technical limitations. In contrast, epigenetic analysis of patient-derived cfDNA is a promising alternative, especially for early detection and disease surveillance, because epigenetic modifications are tissue-specific and reflect the dynamic process of cancer progression. Therefore, cfDNA-based epigenetic assays are emerging to be a highly sensitive, minimally invasive tool for cancer diagnosis and prognosis with great potential in future precise care of cancer patients. The major obstacle for applying epigenetic analysis of cfDNA, however, has been the lack of enabling techniques with high sensitivity and technical robustness. In this review, we summarized the advances in epigenome-wide profiling of 5-hydroxymethylcytosine (5hmC) in cfDNA, focusing on the detection approaches and potential role as biomarkers in different cancer types.

AB - Robust and clinically convenient biomarkers for cancer diagnosis, early detection, and prognosis have great potential to improve patient survival and are the key to precision medicine. The advent of next-generation sequencing technologies enables a more sensitive and comprehensive profiling of genetic and epigenetic information in tumor-derived materials. Researchers are now able to monitor the dynamics of tumorigenesis in new dimensions, such as using circulating cell-free DNA (cfDNA) and tumor DNA (ctDNA). Mutation-based assays in liquid biopsy cannot always provide consistent results across studies due partly to intra- and inter-tumoral heterogeneity as well as technical limitations. In contrast, epigenetic analysis of patient-derived cfDNA is a promising alternative, especially for early detection and disease surveillance, because epigenetic modifications are tissue-specific and reflect the dynamic process of cancer progression. Therefore, cfDNA-based epigenetic assays are emerging to be a highly sensitive, minimally invasive tool for cancer diagnosis and prognosis with great potential in future precise care of cancer patients. The major obstacle for applying epigenetic analysis of cfDNA, however, has been the lack of enabling techniques with high sensitivity and technical robustness. In this review, we summarized the advances in epigenome-wide profiling of 5-hydroxymethylcytosine (5hmC) in cfDNA, focusing on the detection approaches and potential role as biomarkers in different cancer types.

KW - 5-Hydroxymethylcytosine

KW - Cancer biomarker

KW - Cell-free DNA

KW - Epigenetics

KW - Liquid biopsy

UR - http://www.scopus.com/inward/record.url?scp=85063723469&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85063723469&partnerID=8YFLogxK

U2 - 10.1186/s40880-019-0356-x

DO - 10.1186/s40880-019-0356-x

M3 - Review article

VL - 39

JO - Cancer Communications

JF - Cancer Communications

SN - 1000-467X

IS - 1

M1 - 12

ER -